Press release, Helsinki, 5 May 2026 at 9 AM (EEST)
Nexstim Receives NBS 6 System Order from Children’s Hospital in the U.S.
Nexstim Plc ("Nexstim" or "Company") announces having received an order for an NBS 6 system from a new customer in the United States. The customer is a renowned pediatric hospital that is acquiring the system for neuroscience and therapy use.
The NBS System 6 is FDA-cleared for pre-surgical mapping of the speech and motor cortices of the brain, as well as for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in adult and adolescent patients. The NBS 6 is also FDA-cleared as an adjunct for the treatment of adult patients suffering from Obsessive Compulsive Disorder (OCD). The system ordered includes motor mapping and therapy modules.
The NBS 6 is a new product generation that enables Nexstim’s unique E-field navigated TMS technology to be used more easily than ever before. Part of this system is an easy-to-use, software-guided application and a modular product design that allows for system capabilities to expand over time and be highly customized based on a customer’s research or clinical interests.
Mikko Karvinen, CEO of Nexstim, comments: “We are honored to see our latest version of our technology selected by a leading U.S. children’s hospital. Pediatric research environments place particularly high demands on precision, safety, and flexibility, and we are proud that our NBS 6 system can support clinicians and researchers in this highly specialized setting.”
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the NBS System 6, which is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of Major Depressive Disorder (MDD) in adult and adolescent patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode, and as an adjunct for the treatment of adult patients suffering from Obsessive Compulsive Disorder (OCD). In Europe, the NBS 6 system is CE-marked for the treatment of major depression, chronic neuropathic pain as well as post-operative rehabilitation of motor deficits of the upper limb.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com.